Apyx Medical Secures $7 Million Funding Through Direct Offering
The company known for its innovative energy technology solutions, Apyx Medical Corporation, has made a significant move in the financial market by announcing a registered direct offering that raises approximately $7 million. This announcement highlights a strategic investment aimed at fostering the company’s growth and expanding its operations.
Details of the Offering
Apyx Medical, operating under the ticker symbol NASDAQ:APYX, entered into a definitive purchase agreement with Nantahala Capital that facilitates the sale of 3 million shares of common stock. Each share is priced at $1.18, aligning with the market trends and investor confidence observed over the preceding days. Additionally, pre-funded warrants were included in the offering, allowing the purchase of an additional 2,934,690 shares, bringing further investment opportunities to potential investors.
Utilization of Proceeds
The capital raised through this offering is set to be dedicated primarily to working capital and general corporate purposes. This strategic allocation emphasizes the company's commitment to enhancing its operational capabilities and preparing for future advancements within the medical technology sector.
The Business Strategy of Apyx Medical
Apyx Medical continues to innovate within the advanced energy technology landscape, particularly with its proprietary Helium Plasma and radiofrequency platform technologies. These products, marketed as Renuvion® and J-Plasma®, are transformative in the fields of cosmetic surgeries and hospital surgical procedures. With the backing of over 90 clinical documents, Apyx Medical is positioned as a leader in delivering precise and controlled thermal energy to tissue, enhancing surgical outcomes significantly.
Market Position and Potential
With the release of new funding, Apyx Medical is keen on enhancing its market position in a highly competitive field. The medical device industry continuously evolves, and Apyx is poised to leverage its core technologies and research capabilities to introduce new products and solutions. Their focus on OEM agreements with other manufacturers ensures robust partnerships that could lead to groundbreaking advancements in medical technology.
The Future Looks Bright for Apyx Medical
Apyx Medical's recent efforts demonstrate a proactive response to opportunities in the market. With a committed approach to innovation and partnership, the company is likely to navigate the challenges and uncertainties prevalent in the industry effectively. From securing funds through direct offerings to developing state-of-the-art technologies, Apyx Medical illustrates resilience and foresight in an ever-evolving healthcare landscape.
Investor Relations
The company invites interested parties to learn more about this investment opportunity through their investor relations representatives. Jeremy Feffer from LifeSci Advisors can provide deeper insight into the company’s progress and future initiatives. Potential investors can also reach out via email for inquiries or additional information.
Frequently Asked Questions
What is the purpose of Apyx Medical's direct offering?
The proceeds from the direct offering will primarily be used for working capital and general corporate purposes, facilitating technology development and operational growth.
How many shares were offered in the registered direct offering?
A total of 3 million shares of Apyx Medical's common stock were offered, along with pre-funded warrants for up to 2,934,690 additional shares.
What are Renuvion® and J-Plasma®?
Renuvion® and J-Plasma® are proprietary products by Apyx Medical that utilize helium plasma and radiofrequency technology for precision surgical procedures in cosmetic and hospital settings.
How does Apyx Medical's offering compare to market trends?
The offering price of $1.18 per share reflects the average closing price of the company’s stock, indicating strong investor interest and market support.
Who can I contact for more information about Apyx Medical?
For more details regarding investments and company information, you can contact Jeremy Feffer, Managing Director at LifeSci Advisors, via email.
